LONGMONT, Colo., Oct. 1 /PRNewswire/ -- Chemizon (010170, KOSDAQ) announced today that it has reached an agreement with Takeda Pharmaceutical Company Limited, to expand its current research collaboration focused on utilizing Chemizon's discovery platform.
As part of the agreement, Chemizon will commit a majority of its current Korean site to the Takeda partnership. In addition, Chemizon will expand its Korean operations to accommodate future growth.
"Takeda is a premier global pharmaceutical company and we are delighted that they have chosen Chemizon as a preferred partner," said Dr. Tony Piscopio, Chairman and CEO of Chemizon. "Our highly motivated scientific team's commitment to excellence remains the foundation for Chemizon's rapid growth. As we add biology capabilities to our integrated discovery platform, our partners will be able to leverage a number of additional options that will become available in the near future."
About Chemizon Inc.:
Chemizon, a division of Optomagic Co. Ltd., is a global provider of drug discovery and development capabilities to the pharmaceutical industry. Anchored by an experienced management team, Chemizon combines its vertically integrated discovery platform with a flexible, collaborative business model to develop best-in-class clinical candidates. Our expertise spans a broad range of therapeutic areas and target classes. In addition to providing an integrated discovery solution, we assist our collaborators with stand alone services including: lead optimization, library design and synthesis, custom synthesis, radiolabeling, ADME profiling, analytical method development and process chemistry.
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with
its main focus on pharmaceuticals.
|SOURCE Chemizon Inc.|
Copyright©2007 PR Newswire.
All rights reserved